BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price hoisted by equities research analysts at Royal Bank of Canada to $16.00 in a research report issued on Tuesday, The Fly reports. The brokerage presently has a “positive” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price suggests a potential upside of 79.98% from the company’s previous close.
Several other equities analysts have also recently issued reports on the company. BidaskClub upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 23rd. Piper Jaffray Companies started coverage on BioCryst Pharmaceuticals in a research report on Friday, November 16th. They set an “overweight” rating and a $15.00 target price on the stock. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. ValuEngine upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 12th. Finally, JMP Securities boosted their target price on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 5th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. BioCryst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $11.41.
Shares of BCRX stock opened at $8.89 on Tuesday. The stock has a market capitalization of $974.71 million, a P/E ratio of -11.40 and a beta of 1.78. BioCryst Pharmaceuticals has a 52-week low of $4.25 and a 52-week high of $9.70. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.98 and a current ratio of 2.00.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.03). The company had revenue of $1.45 million during the quarter, compared to analyst estimates of $2.53 million. BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 141.00%. As a group, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.99 EPS for the current fiscal year.
In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 15,500 shares of the business’s stock in a transaction that occurred on Friday, November 23rd. The stock was sold at an average price of $9.32, for a total transaction of $144,460.00. Following the transaction, the insider now owns 142,383 shares in the company, valued at approximately $1,327,009.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas R. Staab II sold 9,850 shares of the business’s stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the transaction, the insider now owns 140,633 shares in the company, valued at approximately $1,018,182.92. The disclosure for this sale can be found here. Insiders have sold a total of 131,640 shares of company stock worth $1,127,702 in the last quarter. 4.50% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP grew its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the 3rd quarter. Baker BROS. Advisors LP now owns 15,103,081 shares of the biotechnology company’s stock worth $115,237,000 after acquiring an additional 1,090,909 shares during the period. Janus Henderson Group PLC grew its holdings in shares of BioCryst Pharmaceuticals by 10.4% in the 3rd quarter. Janus Henderson Group PLC now owns 12,250,161 shares of the biotechnology company’s stock worth $93,469,000 after acquiring an additional 1,153,978 shares during the period. BlackRock Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 13.1% in the 3rd quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock worth $66,914,000 after acquiring an additional 1,013,905 shares during the period. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 9.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,798,229 shares of the biotechnology company’s stock worth $44,240,000 after acquiring an additional 490,319 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of BioCryst Pharmaceuticals by 10.9% in the 3rd quarter. Jennison Associates LLC now owns 3,850,003 shares of the biotechnology company’s stock worth $29,376,000 after acquiring an additional 378,565 shares during the period. Institutional investors own 91.34% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Story: How to use beta for portfolio diversification
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.